Comparison of Two Doses of Intravitreal Bevacizumab (Avastin) for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

Wu, Lihteh; Arévalo, J. Fernando; Roca, José A.; Maia, Maurício; Berrocal, María H.; Rodriguez, Francisco J.; Evans, Teodoro; Costa, Rogério A.; Cardillo, J.A.

doi:10.1097/iae.0b013e3181619bee

Cited by 99 publications

(67 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, there have been other reports of short-term beneficial effect of intravitreal bevacizumab to treat macular oedema secondary to retinal vascular disease, including branch retinal vein occlusion 24,25 and diabetic retinopathy. 26,27 More recently, Ferrara et al 28 reported a dramatic improvement in the visual acuity and clinical fundus appearance with significant macular thickness reduction after the early intravitreal bevacizumab injections.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion

2009

Eye

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion

2009

Eye

View full text Add to dashboard Cite

show abstract

“…Doses of bevacizumab used in the literature have ranged from 1.25 to 2.5 mg. 10,11,20,21 We chose the higher dose of 2.5 mg in this study in the hopes of prolonging the therapeutic effect and reducing the number of repeated injections. The average number of injections in this study was 1.4 in a 6-month follow-up.…”

Section: Figmentioning

confidence: 99%

Intravitreal Bevacizumab (Avastin) and Panretinal Photocoagulation in the Treatment of High-Risk Proliferative Diabetic Retinopathy

Yang

Hung

Huang

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: To report the short-term efficacy and safety of intravitreal bevacizumab (Avastin) injection with panretinal laser photocoagulation (PRP) in patients with high-risk proliferative diabetic retinopathy (PDR) according to the Early Treatment Diabetic Retinopathy Study criteria. Methods: A prospective, interventional case series study was conducted in 17 patients (20 eyes) with high-risk PDR, who were treated with intravitreal bevacizumab (2.5 mg) followed by PRP when the peripheral vitreous became clear or 2 weeks after injection. Patients underwent complete ophthalmic evaluation, including Snellen visual acuity and fluorescein angiography at baseline, 1, 3, and 6 months after bevacizumab injection. Main outcome measures included the serial changes in visual acuity, vitreous clear-up time, and neovascularization on the disc (NVD) regression time. Results: All patients had obvious reduction in angiographic leakage and involution of retinal neovascularization (NV) at the 1-and 3-month follow-up. The mean follow-up time was 7.5 months. The vitreous hemorrhage (VH) showed a partial resolution as early as 1 week, and complete regression at 3 months. The mean vitreous clear-up time after intravitreal Avastin was 8.5 -2.2 weeks. The mean time interval from intravitreal Avastin to NVD regression was 10.8 -3.4 weeks. Mean logarithm of the minimum angle resolution visual acuity improved from 1.03 at baseline to 0.36 at 1-month, 0.38 at 3-month, and 0.48 at the 6-month follow-up (P < 0.01). Three eyes (18%) required vitrectomy surgery during follow-up. The indication for vitrectomy was dense, persistent VH in 2 eyes, and focal tractional retinal detachment (TRD) in 1 eye. Recurrent retinal NV with minor preretinal hemorrhage was observed in 6 eyes (30%) 3 months after the first injection, and resolved after repeated bevacizumab injections. Patients received an average of 1.4 injections (range: 1-2). Seven eyes (35%) underwent 2 injections. One eye (5%) had ocular complication of PDR progression to TRD. No systemic adverse events were observed following injections. Conclusions: Short-term results suggest combined intravitreal bevacizumab and PRP achieved rapid clearance of VH, regression of retinal NV, and visual improvement in the treatment of high-risk PDR. Long-term study is warranted to assess the long-term efficacy and safety.

show abstract

“…In several clinical studies bevacizumab, one of anti-VEGF agent, was reported to significantly reduce ME and improve visual function in BRVO. [10][11][12] However, its half-life in vitreous is as short as 4.32 days and its effective concentration is maintained for 30 days, thus multiple injection is usually required for maintaining its effect. 13 Multiple injections of bevacizumab increase the risk of injection-related complications such as vitreous hemorrhage, retinal detachment, and endophthalmitis, and it can be an economic burden to patients.…”

Section: Introductionmentioning

confidence: 99%

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Moon

Kim

Sagong

2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate efficacy and safety of combination therapy of intravitreal bevacizumab (IVB) with single simultaneous posterior subtenon triamcinolone acetonide (STA) for treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods This was a prospective, randomized, interventional comparative study conducted in 45 eyes with ME secondary to BRVO who were treated primarily with IVB 1.25 mg (23 eyes, IVB group) or combination therapy of IVB 1.25 mg with a single simultaneous STA 40 mg (18 eyes, IVB/STA group). Reinjections were performed with IVB if optical coherence tomography (OCT) showed recurrent ME associated with decreased visual acuity. The main outcome measurement was the number of additional IVB injections, and changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) during a 6-month follow-up period were compared. Results BCVA showed significant improvement in two groups at 6 months. In addition, CMT showed significant decrease in two groups at 6 months. No significant differences in the change of BCVA and CMT at 6 months after injection (P = 0.973, P = 0.639) were observed between the two groups. A statistically significant difference was found regarding the number of additional IVB injections (IVB group 0.96 ± 0.83; IVB/STA group 0.44 ± 0.70, P = 0.034).Conclusion Although combination therapy of IVB with a single simultaneous STA for treatment of ME secondary to BRVO did not affect the visual outcomes compared with IVB monotherapy, it had a benefit of reducing the number of additional IVB injections.

show abstract

Comparison of Two Doses of Intravitreal Bevacizumab (Avastin) for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

Cited by 99 publications

References 27 publications

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion

Intravitreal Bevacizumab (Avastin) and Panretinal Photocoagulation in the Treatment of High-Risk Proliferative Diabetic Retinopathy

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Contact Info

Product

Resources

About